Science Committee

Antibiotic Research UK’s research programmes are overseen by the Science Committee consisting of:

  • Dr Joe Standing
    Principal Research Associate, UCL GOS Institute of Child Health
    Science Committee Member

    Joe Standing is an academic pharmacist based in the Mathematical Modelling Section of the Infection, Immunity and Inflammation division at the UCL Great Ormond Street Institute of Child Health. He leads the newly established NIHR UCL Antimicrobial Pharmacodynamics (hollow fibre) research facility, and since 2010 has been the Antimicrobial Pharmacist at Great Ormond Street Hospital. The Paediatric Pharmacometrics research group Joe leads focuses on a range of quantitative clinical pharmacology questions with a primary emphasis on infection and immunity, and in particular drug development of anti-infective agents. Funding includes grants from MRC, Wellcome, NIHR and the EU (FP-7 and H2020). Joe has worked with several academic and industry partners at various stages of antimicrobial, antifungal and antiviral development, and served for 3 years on the European Medicines Agency Modelling and Simulation Working Group.

  • Dr Lloyd Payne
    BSc PhD
    Chair of Science Committee

    Dr Lloyd Payne is a drug discovery executive and anti-infectives specialist with more than 25 years’ industry experience in the Biotech and CRO sectors.  Formerly Executive Vice President, Head of Anti-infectives Operations at Evotec, a multinational preclinical drug discovery organisation, Lloyd led global anti-infective operations and sat on the executive committee for Evotec’s global CRO business. Prior to Evotec, Lloyd was the founding CEO of Euprotec, a leading biology anti-infectives CRO focused on the discovery and development of new antimicrobial agents. He led the company from foundation in 2008 through significant growth, collaborating with numerous organisations worldwide, and to a successful sale and integration into Evotec in 2014.

    Prior to co-founding Euprotec, Dr Payne was a medicinal chemist and worked on a range of programs in the oncology, inflammation, and infectious disease therapeutic areas. Lloyd has a strong passion for creating and building innovative partnerships and has led multiple collaborations developing new drugs to treat serious infections with programs focused on innovation, novel classes, mechanisms and modalities.

    Lloyd is a voice for change in the global AMR and antibiotic discovery and development community, is a member of the Novo REPAIR Impact Fund Scientific Selection Board and advises several companies and organisations in the infectious diseases therapy area.

    Lloyd Payne holds a D.Phil. in synthetic organic chemistry, has published research in peer-reviewed journals, presented at international conferences, and is a co-inventor on patents related to drug discovery technologies as well as novel agents for the treatment of cancer, inflammation, and infection.

    Lloyd says “I am delighted to join Antibiotic Research UK as Chair of the Science Committee and I very much look forward to working with the team to foster innovation in the quest to bring potentially life-saving new antibiotics and treatment modalities to the patient. The charity plays a very important role in the UK and global community involved in the effort to discover and develop new antibiotic therapies to treat drug resistant infections. I am very happy to have the opportunity to collaborate with colleagues in the UK and across the world and work together to rebuild a sustainable pipeline of antibiotics and help to promote a critically needed sustainable economic model.”

  • Dr Alan Houston
    Science Committee Member

    Alan Houston is an experienced Pharmaceutical Physician, with a track record of successfully developing new drugs for the EU, US and global markets. He has a varied background in clinical pharmacology, clinical development and pharmacogenomics within top companies.

    He has led research and development teams in the UK, Switzerland, France, Germany, Scandinavia, Japan and the United States.

    Alan qualified in Medicine (MBBS) at the University of London and obtained his specialist qualification in Internal Medicine in London (MRCP). Before joining the Pharma industry, he spent nine years in Internal Medicine in the UK NHS, training in diabetes and endocrinology, and human toxicology, and three years as a clinical pharmacologist at the Chemical Defence Establishment at Porton Down. After joining the pharmaceutical industry, he was awarded the fellowship diploma in Pharmaceutical Medicine (FFPM) with the Faculty of Pharmaceutical Medicine in London.

    He has published on diabetes, human toxicology, maritime and industrial poisoning, and clinical pharmacology.

  • Dr Tina Joshi
    Lecturer in Molecular Microbiology, University of Plymouth
    Science Committee Member

    Dr Tina (Lovleen) Joshi obtained her PhD in Pharmaceutical Microbiology at Cardiff University in 2012. During her PhD she specialised in the development of a diagnostic assay to detect the pathogen Clostridium difficile at point-of-care, leading to 2 granted patents as inventor. After pursuing postdoctoral positions at Cardiff University between 2012-2017, where she developed novel point-of-care diagnostic tests for pathogens including MRSA and Bacillus anthracis, Tina joined the University of Plymouth as a Lecturer in Molecular Microbiology in August 2017.

    Tina has transferred her diagnostics knowledge to the key challenge of developing novel and easy-to-use diagnostics for detection of antibiotic resistant bacteria in infected patients at their bedside/initial consultation. This research has been featured on the BBC One documentary “The Truth about Antibiotics”. Diagnostics, and new antibiotics, are imperative in the war against antibiotic resistant bacteria and will aid clinicians to diagnose infections and undertake appropriate antibiotic stewardship. Moreover, Tina has a strong interest in effective infection control practices in hospital environments and the use of appropriate disinfectants to prevent transmission of resistant bacteria.

    Tina wanted to be involved with ANTRUK as she believes that charity is supporting critical research in the area of antibiotic discovery. The charity is also undertaking important engagement activities to help the public and policy-makers understand more about the devastating impacts of antibiotic resistance. Tina hopes that she can provide relevant expertise to the scientific committee and assist in spreading the message about antibiotic resistance, infection prevention and the charity’s vital research.

  • Dr Mike Allen
    Dr Mike Allen
    Regional Medical Advisor (Antibiotics), MSD Limited, UK
    Science Committee Member

    Mike has over 30 years of UK and Global pharmaceutical industry experience within the field of antibiotics, antimicrobial resistance and infectious disease. Mike started his career as a clinical pharmacologist working with the Pain & Opiate Research Group at the Nuffield Department of Anaesthetics in Oxford from 1979 to 1986, obtaining his DPhil in 1986.

    In January 1987 he joined Lederle Laboratories (later became Wyeth Pharmaceuticals) where he was responsible for the medical activities for piperacillin/tazobactam throughout its lifecycle and the pre and post launch Medical activities for tigecycline from 2003 – 2007. Mike joined Novartis Pharmaceuticals in 2007 as the Medical Development Advisor for antibiotics, with the medical responsibilities for daptomycin, inhaled tobramycin and pipeline antibiotics, for the UK and Region Europe. In February 2015 he joined Cubist Pharmaceuticals, before moving to MSD in April following the acquisition of Cubist by MSD.

    Mike currently works as the Regional Medical Advisor (Antibiotics) and MSD Ltd UK, with medical responsibilities for MSD’s broad portfolio of licensed antibiotics and pipeline molecules. Over his career in the pharmaceutical industry, he has worked collaboratively with medical, commercial, policy and development teams at National, European and Global levels, including the coordination of a highly successful international patient registry and multiple national surveillance studies.

    Mike has co-authored over 40 publications with lead researchers in the UK and internationally, looking particularly at antibiotic resistance surveillance and the association between antibiotic use and infections caused by clinically significant pathogens including; Clostridium difficile, glycopeptide-resistant enterococci, MRSA and ESBL-producing enterobacteriaeceae.

  • Professor Colin Garner PhD DSc FRCPath (Chief Executive)
    Professor Colin Garner
    BPharm PhD DSc FRCPath
    Science Committee Member

    Colin Garner is both a university academic scientist and scientific entrepreneur. He graduated from Chelsea College, University of London (now Kings College) and did his PhD in biochemical toxicology at University College Hospital Medical School. After a two year postdoctoral fellowship at the University of Wisconsin, USA he returned to the UK to carry out cancer research at the University of Leeds and then for the majority of his career at the University of York. He headed up a cancer research laboratory in the Department of Biology for almost 20 years in which time he published over 200 scientific papers and 30 book chapters on the role of gene-environment interactions in cancer causation. Along with two surgeon colleagues, he created the York cancer charity York Against Cancer which provides funds for education, research and patient support.

    Colin founded three University of York spinout companies and is the founder of Antibiotic Research UK. He believe passionately in the new charity and says ‘there is an urgent need to develop new drugs to tackle antibiotic resistant infections as well as educating the public and professionals about antibiotic resistance. Antibiotic Research UK as a charity can make a substantial impact as it is a non-profit organisation. The Charity is working with some of the world’s experts in antibiotic resistance to reach its goal’. Colin was the founder and Director of the Jack Birch Unit for Environmental Carcinogenesis and was an Honorary Professor of Pharmacology at the Hull York Medical School, University of York.

  • Professor Chris G Dowson
    Professor Chris G Dowson
    BSc PhD
    Science Committee Observer

    Professor Chris G Dowson (School of Life Sciences, University of Warwick, UK) has, for many years, examined the emergence and evolution of antibiotic resistance across a wide range of bacteria. His recent focus has been to better understand how penicillin targets bacteria. This began during his postdoctoral time at the University of Sussex, in the laboratory of Professor Spratt (1986-1990) and subsequently with his Lister Institute Centenary Fellowship (1991-1996). He currently holds a personal chair at Warwick University and is a past member of the Medical Research Council Infections and Immunity Board.

    Chris’ research is highly collaborative, involving teams of biologists, chemists, engineers and physicists across universities in the UK, worldwide, and all importantly with industry, to help drive innovations from this research forward to a commercial outcome. He was involved with Antibiotic Discovery UK (AD-UK) and has been involved with research fundraising regionally across Warwickshire for the past 16 years with the Medical and Life Sciences Research Fund (MLSRF). He is bringing all of this experience to help develop activities within Antibiotic Research UK.

  • Dr Mark Sutton
    Scientific Leader – Healthcare Biotechnology at Health Protection Agency
    Science Committee Member

    Dr J. Mark Sutton obtained a PhD in Molecular Microbiology working at the John Innes Institute, Norwich in 1994. During his PhD, he developed a range of expertise in molecular genetics, molecular biology, protein chemistry, recombinant protein purification and microbiology. His PhD was followed by BBSRC-funded post-doctoral fellowships at John Innes and the University of Leeds (1994-1997), working on the generation of disease resistant transgenic plants.

    Mark joined the Centre for Applied Microbiology and Research (CAMR), Porton Down in 1997 (which became part of the Health Protection Agency in 2003 and Public Health England in 2013) and worked on a series of commercially funded studies aiming to develop new medicines derived from the properties of botulinum neurotoxin and other bacterial toxins. This developed a range of skills in molecular microbiology, protein purification, protein structure function analysis and therapeutic development. The work led to a spin out company, Syntaxin Ltd (Now acquired by Ipsen Pharmaceuticals). He spent 10 years leading a series of projects focussed on preventing the transmission of variant Creutzfeldt Jakob Disease (vCJD). These studies led to presentations to UK government advisory groups, with work cited in risks assessments and guidance documents.

    Dr Sutton became a Scientific Leader for Healthcare Biotechnology in 2009 and manages the Technology Development Group, an interdisciplinary research group within PHE’s National Infections Service. The group focusses on developing and evaluating new interventions for the treatment of healthcare associated infections (HCAIs) and antimicrobial resistance. The group developed models to assess applied infection control methods (decontamination, disinfection) and to evaluate new antimicrobial agents, working with a number of chemistry, pharmacy, physical science, electrical engineering and microbiology groups worldwide. The group established a screening and evaluation pathway for assessing the efficacy of new antimicrobials and to enable analysis of resistance that emerges during exposure to antibiotics. This uses a range of in vitro assays, in vivo infection models, with molecular genetics and embedded whole genome sequencing used to understand susceptibility and the emergence of resistance.

    Mark is a visiting Senior Lecturer at King’s College London and represents PHE on a number of advisory boards and committees, nationally and internationally. He is author on more than 60 peer-reviewed publications and a named inventor on 16 patent families, filed internationally.

  • Dr Chris Longshaw
    EU Scientific Advisor, Infectious Diseases, Shionogi Limited, UK
    Science Committee Member

    Chris is a Medical Scientific Affairs Specialist with extensive European pharmaceutical industry experience in the field of Antimicrobial Chemotherapy and Infectious Disease.

    Chris has worked in both Pharmaceutical and Crop Protection sectors, with roles spanning the full product life cycle from early phase Antimicrobial discovery and lead development, through regulatory submissions to post-market commercialization and Medical/Scientific Affairs. Currently Chris is EU Scientific Advisor, Infectious Diseases for Shionogi Pharmaceuticals and works successfully with medical, commercial and development teams at National, European and Global levels to provide medical and scientific leadership.

    Chris also has experience of coordinating microbiology research programmes ranging from large, multi-national epidemiology and resistance surveillance studies to more focused in vitro/in vivo pharmacodynamic studies supporting brand strategy and life cycle management. Chris is a graduate of the University of Leeds where he also obtained his PhD.

  • Dr David Roper
    Professor David Roper
    Professor in Microbiology, Warwick University
    Science Committee Member

    David Roper is a former MRC career Development fellow at the University of York and now reader in Structural Biology at the University Warwick. The Roper group uses structural biology techniques, principally X-ray structural determination, in combination with molecular biology and biochemical approaches, to investigate the molecular basis of microbial physiology in relation to antibiotic resistance and bacterial cell wall (peptidoglycan) biosynthesis in Gram-positive and Gram-negative pathogens.

    In addition, David’s research group also uses synthetic and translational biology approaches to obtain and reengineer pathway intermediates as chemical probes, substrates and inhibitors. This approach not only allows novel insight to the biology underpinning these pathways but also enables biotechnological exploration and exploitation.

    David was recently awarded a Personal Chair by the University of Warwick for his outstanding research contributions.

  • Professor Mark Moloney
    Professor of Organic Chemistry, University of Oxford
    Science Committee Member

    Professor Mark Moloney is currently Professor of Chemistry, having previously been Reader in Chemistry; he completed his undergraduate (B.Sc.(Hons.) and University Medal) and graduate studies (Ph.D. (Chemistry)) at the University of Sydney, Australia.

    On arriving in the UK, Mark embarked on research related to penicillin biosynthesis in the research group of Professor Sir Jack Baldwin FRS, where he worked on photoaffinity labelling studies of IPNS using an approach with diazirine-modified tripeptides to probe the enzyme binding site.

    Mark is currently working on the development of novel antibiotics through the synthesis of hybridised compounds in the hope of tackling antibacterial resistance.

  • Professor Chris Schofield
    Professor and Head of Organic Chemistry, University of Oxford
    Science Committee Member

    Professor Christopher Schofield, FRS is Professor and Head of Organic Chemistry at the University of Oxford, and has world class expertise in the chemical biology of the hypoxic response in humans and other animals with breakthrough work in the field including the identification of the hypoxia inducing factor/hydroxylases and the JmjC prolyl family of oxygenases.

    Chris has published >200 relevant papers (including in ACIE, JACS, Cell, Nature, Nat. Chem., Nat. Commun., PNAS, Science, Science Transl. Med.; >20000 citations; h-index >65). His group is highly collaborative and has been involved in multiple major research initiatives, including the EPSRC Synthesis for Biology and Medicine CDT, Oxford Center for Molecular Science, the Target Discovery Initiate, and others; he has career income for his group’s research of >£15m. Chris and his group are particularly interested in metallo-proteases and the variety of unusual enzymes involved in antibiotic biosynthesis; the carbapenems and clavam families of β-lactams are of particular interest.

  • Dr Lloyd Czaplewski
    Dr. Lloyd Czaplewski
    Chief Scientific Officer, Persica Pharmaceuticals
    Science Committee Member

    Lloyd has over 23-years of R&D experience in biological and chemical entities across multiple therapeutic areas at technical, managerial and corporate levels. For the last 15-years Lloyd has focused on antibacterial R&D, especially DNA supercoiling and bacterial cell wall biosynthesis. Career highlights include a demonstrated ability to create and lead structure-informed screening, hit & lead optimization programmes leading to compounds with class leading in vivo efficacy.

    Lloyd is a prolific inventor with a strong patent (26) and publication (34) record. He has created, managed and buillt Venture Capital funded businesses. Lloyd has a strong record of fund raising (£>23m) from UK, Europe, USA and Japan including charities (Wellcome Trust), Government (DTI, UK & NIAID, USA), Corporate (Astellas), VC investment groups and business angels. He is currently Chief Scientific Officer of Persica Pharmaceuticals.

  • Dr David Wareham
    Dr David Wareham
    Clinical Senior Lecturer / Honorary Consultant in Microbiology, Centre for Immunology and Infectious Disease, Blizard Institute, Barts and The London School of Medicine and Dentistry
    Science Committee Deputy Chair

    David Wareham qualified (MBBS) from the London Hospital Medical College in 1994 and trained in general medicine before specialist training in Medical Microbiology (FRCPath).

    He was awarded a Clinical Training Fellowship to study aspects of Pseudomonas aeruginosa pathogenicity at Queen Mary University in 2002 and appointed as Senior Clinical Lecturer in Microbiology in July 2005 (PhD).

    David is an Honorary Consultant Microbiologist at Barts Health NHS Trust responsible for aspects of intensive care microbiology. He heads the Antimicrobial Research Group which is involved in characterizing the mechanisms underlying the development and persistence of antimicrobial resistance as well as the consequences this may have on the organism and its capacity to cause human disease. This combines genomics, molecular biology, in-vitro and in-vivo (invertebrates) studies, epidemiological and clinical data in an attempt to dissect the complex relationship between host, pathogen and resistance. Research is driven by problems encountered in daily clinical practice and in recent years has focused on multi-drug resistant Gram-negative bacteria such as Acinetobacter baumannii, Stenotrophomonas maltophilia and carbapenem resistant Enterobacteria. Areas of particular interest include the identification of novel resistance determinants, evaluation of novel antimicrobial treatments, pharmacodynamic and pharmacokinetic analysis of new and repurposed combination therapies, virulence studies of emerging pathogens and interventions to prevent the spread of resistant organisms in the hospital environment.